Genmab | GEN - Equity Capital And Reserves



Genmab reported DKK5.3B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
Almirall EUR 1.46B 37.19M Jun/2025
Amarin USD 473.69M 12.49M Mar/2025
Amgen USD 7.43B 1.22B Jun/2025
argenx SE 6.1B 597.47M Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Bayer EUR 30.5B 2.08B Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Demant DKK 9.4B 168M Jun/2025
Exelixis USD 2.03B 97.49M Jul/2025
Fresenius Medical Care EUR 14.33B 1.18B Jun/2025
Galapagos EUR 2.64B 104.07M Jun/2025
Genmab DKK 5.3B 6M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
GN Store Nord DKK 10.45B 304M Jun/2025
GRIFOLS EUR 7.6B 1.96B Jun/2025
Hikma Pharmaceutical USD 2.32B 35M Dec/2024
Insmed USD 1.25B 1.15B Jun/2025
Lonza CHF 9.33B 23M Dec/2024
Merck EUR 28.26B 1.64B Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
UCB EUR 10.03B 1.08B Dec/2024